Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms FIGARO UC 301
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 27 Oct 2021 Results assessing the clinical remission threshold for the UC e-diary using data from 2 Phase 3 trials (NCT03259334 and NCT03259308) of patients with ulcerative colitis, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
- 27 Oct 2021 Results assess the psychometric properties of the UC e-diary in Adult patients with moderate-to-severe ulcerative colitis from NCT03259334 and NCT03259308, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 12 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.